Family 1 G protein-coupled receptor function in the CNS: Insights from gene knockout mice

Brain Research Reviews

Volumn 41, Issue 2-3, 2003, Pages 125-152

  Karasinska, Joanna M ^a   George, Susan R ^a,b   O'Dowd, Brian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Behaviour; Central nervous system; G protein coupled receptor; Gene knockout mice

Indexed keywords

ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR; BOMBESIN RECEPTOR; CANNABINOID RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE RECEPTOR; HORMONE; LIGAND; MUSCARINIC RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROTRANSMITTER; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR; TACHYKININ RECEPTOR;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM FUNCTION; GENE TARGETING; KNOCKOUT MOUSE; NONHUMAN; PHOTON; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR GENE; REVIEW;

EID: 0037347147     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(02)00221-7     Document Type: Review

References (359)

1. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. USA. 93:1996;1945-1949.
2. 2A-adrenergic receptor knockout mice. Mol. Pharmacol. 56:1999;154-161.
3. 2A receptor antagonist. J. Neurosci. 20:2000;5848-5852.
4. 1A-dopamine receptor-deficient mouse. Dev. Neurosci. 20:1998;237-241.
5. (1B) receptor knockout mice. J. Neurochem. 75:2000;2415-2426.
6. 1B knockout. J. Neurochem. 78:2001;619-630.
7. 2 receptors. Nature. 377:1995;424-428.
8. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
9. Battey J., Wada E. Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends Neurosci. 14:1991;524-528.
10. Baynash A.G., Hosoda K., Giaid A., Richardson J.A., Emoto N., Hammer R.E., Yanagisawa M. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell. 79:1994;1277-1285.
11. 1 receptor deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 363:2001;562-568.
12. Belzung C., Scearce-Levie K., Barreau S., Hen R. Absence of cocaine-induced place conditioning in serotonin 1B receptor knock-out mice. Pharmacol. Biochem. Behav. 66:2000;221-225.
13. 1 receptor is essential for the full expression of noxious inhibitory controls in the mouse. J. Neurosci. 21:2001;1039-1046.
14. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18:1999;1723-1729.
15. 1 receptors. Neuroscience. 95:2000;5-7.
16. Bolivar V., Cook M., Flaherty L. List of transgenic and knockout mice: behavioral profiles. Mamm. Genome. 11:2000;260-274.
17. Boring L., Gosling J., Chensue S.W., Kunkel S.L., Farese R.V. Jr., Broxmeyer H.E., Charo I.F. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:1997;2552-2561.
18. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J. Biol. Chem. 270:1995;13706-13710.
19. 3 receptor agonists. Neuropharmacology. 38:1999;1389-1396.
20. 1B knock-out mice. J. Neurosci. 19:1999;3204-3212.
21. 1B knockout mice. Biol. Psychiatry. 49:2001;557-568.
22. 1B receptor knockout mice. Eur. J. Pharmacol. 403:2000;95-98.
23. Bozic C.R., Lu B., Hopken U.E., Gerard C., Gerard N.P. Neurogenic amplification of immune complex inflammation. Science. 273:1996;1722-1725.
24. 2 receptor leads to a decreased expression of GDNF and NT-4 mRNAs in restricted brain areas. Eur. J. Neurosci. 11:1999;1275-1284.
25. Bozzi Y., Vallone D., Borrelli E. Neuroprotective role of dopamine against hippocampal cell death. J. Neurosci. 20:2000;8643-8649.
26. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog. Neurobiol. 63:2001;637-672.
27. Brunner D., Hen R. Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice. Ann. NY Acad. Sci. 836:1997;81-105.
28. 2 receptor. Eur. J. Pharmacol. 396:2000;141-149.
29. Butler A.A., Kesterson R.A., Khong K., Cullen M.J., Pelleymounter M.A., Dekoning J., Baetscher M., Cone R.D. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology. 141:2000;3518-3521.
30. Cacalano G., Lee J., Kikly K., Ryan A.M., Pitts-Meek S., Hultgren B., Wood W.I., Moore M.W. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science. 265:1994;682-684.
31. 2 receptors. J. Neurosci. 17:1997;4536-4544.
32. Cao Y.Q., Mantyh P.W., Carlson E.J., Gillespie A.M., Epstein C.J., Basbaum A.I. Primary afferent tachykinins are required to experience moderate to intense pain. Nature. 392:1998;390-394.
33. Capecchi M.R. Targeted gene replacement. Sci. Am. 270:1994;52-59.
34. 3 dopamine receptor-deficient mice. Neuroreport. 11:2000;2395-2399.
35. 1b-adrenergic receptor. Proc. Natl. Acad. Sci. USA. 94:1997;11589-11594.
36. 2 dopamine receptor-deficient mice. J. Neurophysiol. 85:2001;659-670.
37. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 98:1999;437-451.
38. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., Rosenblum C.I., Vongs A., Feng Y., Cao L., Metzger J.M., Strack A.M., Camacho R.E., Mellin T.N., Nunes C.N., Min W., Fisher J., Gopal-Truter S., MacIntyre D.E., Chen H.Y., Van der Ploeg L.H. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26:2000;97-102.
39. 2A adenosine receptors. Neuroscience. 97:2000;195-204.
40. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:1999;9192-9200.
41. 2 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 98:2001;1970-1975.
42. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21:2001;RC143.
43. 5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 91:1997;789-798.
44. Chensue S.W., Lukacs N.W., Yang T.Y., Shang X., Frait K.A., Kunkel S.L., Kung T., Wiekowski M.T., Hedrick J.A., Cook D.N., Zingoni A., Narula S.K., Zlotnik A., Barrat F.J., Napolitano M., Lira S.A. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. Exp. Med. 193:2001;573-584.
45. 2 adrenergic receptor gene. J. Biol. Chem. 274:1999;16694-16700.
46. 2 dopamine receptor 'knockout'. Neuropsychopharmacology. 25:2001;527-536.
47. 1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology. 37:1998;1595-1602.
48. 2 dopamine receptor. Neuropharmacology. 39:2000;382-390.
49. Clouthier D.E., Hosoda K., Richardson J.A., Williams S.C., Yanagisawa H., Kuwaki T., Kumada M., Hammer R.E., Yanagisawa M. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 125:1998;813-824.
50. Connolly A.J., Ishihara H., Kahn M.L., Farese R.V. Jr., Coughlin S.R. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 381:1996;516-519.
51. A1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. USA. 97:2000;13384-13389.
52. 6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 12:2000;495-503.
53. 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. 118:2001;61-65.
54. 1B serotonin receptors. Nat. Genet. 14:1996;98-101.
55. Crabbe J.C., Wahlsten D., Dudek B.C. Genetics of mouse behavior: interactions with laboratory environment. Science. 284:1999;1670-1672.
56. 1A-deficient mouse. Neuroreport. 8:1997;2523-2527.
57. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 835:1999;18-26.
58. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacol. (Berl.). 132:1997;107-124.
59. 1A-deficient mutant mice. Eur. J. Neurosci. 10:1998;2426-2432.
60. 2 receptor-deficient mice. Pharmacol. Biochem. Behav. 67:2000;693-699.
61. 2A receptor-deficient mice. Synapse. 42:2001;63-76.
62. 2A receptors. J. Neurochem. 78:2001;183-198.
63. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J., Laird J.M., Belmonte C., Cervero F., Hunt S.P. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 392:1998;394-397.
64. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J. Neurochem. 72:1999;148-156.
65. Dierich A., Sairam M.R., Monaco L., Fimia G.M., Gansmuller A., LeMeur M., Sassone-Corsi P. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc. Natl. Acad. Sci. USA. 95:1998;13612-13617.
66. 1A receptor knockout mice, show reduced startle reactivity and footshock-induced sensitization, as measured with the acoustic startle response. Behav. Brain Res. 118:2001;169-178.
67. 2 receptor is critical in mediating opiate motivation only in opiate-dependent and withdrawn mice. Eur. J. Neurosci. 13:2001;995-1001.
68. 2 receptor-deficient mice. Eur. J. Pharmacol. 365:1999;125-131.
69. 1A dopamine receptors. Proc. Natl. Acad. Sci. USA. 91:1994;12564-12568.
70. 1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience. 74:1996;813-823.
71. 4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19:1999;9550-9556.
72. Dulawa S.C., Gross C., Stark K.L., Hen R., Geyer M.A. Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition. Neuropsychopharmacology. 22:2000;650-659.
73. 1B knockout mice. Psychopharmacol. (Berl.). 132:1997;125-134.
74. 5 receptor: a silent or emerging subtype? Br. J. Pharmacol. 130:2000;13-21.
75. Eguchi N., Minami T., Shirafuji N., Kanaoka Y., Tanaka T., Nagata A., Yoshida N., Urade Y., Ito S., Hayaishi O. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc. Natl. Acad. Sci. USA. 96:1999;726-730.
76. 2A receptors. Br. J. Pharmacol. 129:2000;1465-1473.
77. 2A receptor knockout mice. Br. J. Pharmacol. 134:2001;68-77.
78. 2A receptor knockout mice are partially protected against drug-induced catalepsy. Neuroreport. 12:2001;983-986.
79. 2A receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology. 40:2001;424-432.
80. 1 receptor knockout mice. Eur. J. Pharmacol. 383:1999;95-106.
81. 1 receptor gene expression attenuates alcohol-seeking behavior. Eur. J. Pharmacol. 353:1998;149-158.
82. 1 receptor. Brain Res. 892:2001;86-93.
83. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 381:1996;415-421.
84. Felder C.C., Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38:1998;179-200.
85. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., Befort K., Gaveriaux-Ruff C., Dierich A., LeMeur M., Valverde O., Maldonado R., Kieffer B.L. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25:2000;195-200.
86. 3 receptors for prostaglandin E2. Am. J. Physiol. 275:1998;F955-961.
87. 1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 87:1996;1037-1047.
88. 7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 99:1999;23-33.
89. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;364-374.
90. 1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J. Neurosci. 21:2001;8188-8197.
91. Fuchs P.N., Roza C., Sora I., Uhl G., Raja S.N. Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice. Brain Res. 821:1999;480-486.
92. 2-like receptor subtypes in the mouse brain. Peptides. 22:2001;335-341.
93. Gao J.L., Lee E.J., Murphy P.M. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med. 189:1999;657-662.
94. Gao J.L., Wynn T.A., Chang Y., Lee E.J., Broxmeyer H.E., Cooper S., Tiffany H.L., Westphal H., Kwon-Chung J., Murphy P.M. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med. 185:1997;1959-1968.
95. 1B receptor knockout mice. Eur. J. Pharmacol. 421:2001;171-175.
96. Gaveriaux-Ruff C., Matthes H.W., Peluso J., Kieffer B.L. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc. Natl. Acad. Sci. USA. 95:1998;6326-6330.
97. 1 protects against pancreatitis-associated lung injury. J. Clin. Invest. 100:1997;2022-2027.
98. 1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 98:2001;15312-15317.
99. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 19:1996;177-181.
100. Gingrich J.A., Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacol. (Berl.). 155:2001;1-10.
101. Glickstein S.B., Schmauss C. Dopamine receptor functions: lessons from knockout mice. Pharmacol. Ther. 91:2001;63-83.
102. 2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;1692-1697.
103. 4 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;10483-10488.
104. 5A receptor. Neuron. 22:1999;581-591.
105. 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature. 416:2002;396-400.
106. Haas H.L., Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;375-381.
107. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:2001;1-4.
108. Hall F.S., Sora I., Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacol. (Berl.). 154:2001;43-49.
109. Hamilton S.E., Loose M.D., Qi M., Levey A.I., Hille B., McKnight G.S., Idzerda R.L., Nathanson N.M. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc. Natl. Acad. Sci. USA. 94:1997;13311-13316.
110. Hampton L.L., Ladenheim E.E., Akeson M., Way J.M., Weber H.C., Sutliff V.E., Jensen R.T., Wine L.J., Arnheiter H., Battey J.F. Loss of bombesin-induced feeding suppression in gastrin-releasing peptide receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 95:1998;3188-3192.
111. 4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. Exp. Med. 192:2000;433-438.
112. Hasenohrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., Huston J.P. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides. 34:2000;272-280.
113. 1 reveals a role for fractalkine in cardiac allograft rejection. J. Clin. Invest. 108:2001;679-688.
114. 1A receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in vivo microdialysis. Brain Res. 902:2001;11-17.
115. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 402:1999;181-184.
116. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 377:1995;744-747.
117. 1A receptor mutant mice. Proc. Natl. Acad. Sci. USA. 95:1998;15049-15054.
118. 1 receptor agonist, Ro64-6198, on rodent neurological function. Neuropharmacology. 41:2001;97-107.
119. 5 receptor null mutant mice. Behav. Neurosci. 115:2001;1129-1144.
120. Homanics G.E., Quinlan J.J., Firestone L.L. Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Pharmacol. Biochem. Behav. 63:1999;21-26.
121. Hopken U.E., Lu B., Gerard N.P., Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 383:1996;86-89.
122. Hosoda K., Hammer R.E., Richardson J.A., Baynash A.G., Cheung J.C., Giaid A., Yanagisawa M. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell. 79:1994;1267-1276.
123. 35S]GTPgammaS binding in mu receptor knockout mice. Eur. J. Pharmacol. 388:2000;241-248.
124. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., Hayaishi O. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. USA. 98:2001;9965-9970.
125. Humphries M.M., Rancourt D., Farrar G.J., Kenna P., Hazel M., Bush R.A., Sieving P.A., Sheils D.M., McNally N., Creighton P., Erven A., Boros A., Gulya K., Capecchi M.R., Humphries P. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat. Genet. 15:1997;216-219.
126. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141.
127. Hutcheson D.M., Matthes H.W., Valjent E., Sanchez-Blazquez P., Rodriguez-Diaz M., Garzon J., Kieffer B.L., Maldonado R. Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. Eur. J. Neurosci. 13:2001;153-161.
128. Ichiki T., Labosky P.A., Shiota C., Okuyama S., Imagawa Y., Fogo A., Niimura F., Ichikawa I., Hogan B.L., Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 377:1995;748-750.
129. 2C-Adrenoceptors modulate the effect of methylphenidate on response rate and discrimination accuracy in an operant test. Brain Res. Bull. 54:2001;553-557.
130. 1 receptors. Proc. Natl. Acad. Sci. USA. 93:1996;13316-13320.
131. Ishii S., Kuwaki T., Nagase T., Maki K., Tashiro F., Sunaga S., Cao W.H., Kume K., Fukuchi Y., Ikuta K., Miyazaki J., Kumada M., Shimizu T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187:1998;1779-1788.
132. Ito M., Oliverio M.I., Mannon P.J., Best C.F., Maeda N., Smithies O., Coffman T.M. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc. Natl. Acad. Sci. USA. 92:1995;3521-3525.
133. Jang C.G., Lee S.Y., Park Y., Ma T., Loh H.H., Ho I.K. Differential effects of morphine, DPDPE, and U-50488 on apomorphine-induced climbing behavior in mu-opioid receptor knockout mice. Mol. Brain Res. 94:2001;197-199.
134. 1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;9407-9412.
135. Jordan B.A., Cvejic S., Devi L.A. Opioids and their complicated receptor complexes. Neuropsychopharmacology. 23:2000;S5-S18.
136. 3 receptor genes leads to different alterations in the expression of striatal calbindin-D(28k). Neuroscience. 97:2000;495-504.
137. 3 receptors. J. Biol. Chem. 274:1999;29406-29412.
138. 2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. Neuroscience. 91:1999;911-924.
139. 3 receptors. Eur. J. Pharmacol. 399:2000;171-181.
140. 2 receptor-deficient mice. Neuron. 19:1997;103-113.
141. 2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosci. 18:1998;3470-3479.
142. 2 receptor. Nat. Med. 5:1999;217-220.
143. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 20:1999;19-26.
144. Kim H.S., Krege J.H., Kluckman K.D., Hagaman J.R., Hodgin J.B., Best C.F., Jennette J.C., Coffman T.M., Maeda N., Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. USA. 92:1995;2735-2739.
145. King M.A., Bradshaw S., Chang A.H., Pintar J.E., Pasternak G.W. Potentiation of opioid analgesia in dopamine 2 receptor knock-out mice: evidence for a tonically active anti-opioid system. J. Neurosci. 21:2001;7788-7792.
146. King T.E., Heath M.J., Debs P., Davis M.B., Hen R., Barr G.A. The development of the nociceptive responses in neurokinin-1 receptor knockout mice. Neuroreport. 11:2000;587-591.
147. Kitanaka N., Sora I., Kinsey S., Zeng Z., Uhl G.R. No heroin or morphine 6beta-glucuronide analgesia in mu-opioid receptor knockout mice. Eur. J. Pharmacol. 355:1998;R1-3.
148. Kitchen I., Slowe S.J., Matthes H.W., Kieffer B. Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res. 778:1997;73-88.
149. 1b-adrenoceptor. Eur. Neuropsychopharmacol. 10:2000;423-427.
150. 1B receptor in the mouse. J. Pharmacol. Exp. Ther. 298:2001;1092-1100.
151. 1B autoreceptors in different brain regions of the mouse. J. Pharmacol. Exp. Ther. 298:2001;1083-1091.
152. Kobayashi K., Morita S., Sawada H., Mizuguchi T., Yamada K., Nagatsu I., Hata T., Watanabe Y., Fujita K., Nagatsu T. Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J. Biol. Chem. 270:1995;27235-27243.
153. 2 receptor-deficient mice. J. Clin. Invest. 105:2000;1741-1749.
154. 3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
155. Konig M., Zimmer A.M., Steiner H., Holmes P.V., Crawley J.N., Brownstein M.J., Zimmer A. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature. 383:1996;535-538.
156. Kopin A.S., Mathes W.F., McBride E.W., Nguyen M., Al-Haider W., Schmitz F., Bonner-Weir S., Kanarek R., Beinborn M. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J. Clin. Invest. 103:1999;383-391.
157. Koster A., Montkowski A., Schulz S., Stube E.M., Knaudt K., Jenck F., Moreau J.L., Nothacker H.P., Civelli O., Reinscheid R.K. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl. Acad. Sci. USA. 96:1999;10444-10449.
158. Kreienkamp H.J., Akgun E., Baumeister H., Meyerhof W., Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett. 462:1999;464-466.
159. Kumar T.R., Wang Y., Lu N., Matzuk M.M. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat. Genet. 15:1997;201-204.
160. 2 chemokine receptor. J. Exp. Med. 186:1997;1757-1762.
161. Kurihara Y., Kurihara H., Suzuki H., Kodama T., Maemura K., Nagai R., Oda H., Kuwaki T., Cao W.H., Kamada N., et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 368:1994;703-710.
162. 1 receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 95:1998;15659-15664.
163. 2 receptor-deficient mice. Brain Res. 792:1998;253-262.
164. Lacourse K.A., Swanberg L.J., Gillespie P.J., Rehfeld J.F., Saunders T.L., Samuelson L.C. Pancreatic function in CCK-deficient mice: adaptation to dietary protein does not require CCK. Am. J. Physiol. 276:1999;G1302-1309.
165. 1 receptor gene. Neuroscience. 98:2000;345-352.
166. 1 receptors in capsaicin-induced pain and hyperalgesia in mice. Pain. 90:2001;97-103.
167. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D., et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
168. Larhammar D., Wraith A., Berglund M.M., Holmberg S.K., Lundell I. Origins of the many NPY-family receptors in mammals. Peptides. 22:2001;295-307.
169. Le L.Q., Kabarowski J.H., Weng Z., Satterthwaite A.B., Harvill E.T., Jensen E.R., Miller J.F., Witte O.N. Mice lacking the orphan g protein-coupled receptor g2a develop a late-onset autoimmune syndrome. Immunity. 14:2001;561-571.
170. 1 receptor knockout mice. Science. 283:1999;401-404.
171. 2A receptor. Nature. 388:1997;674-678.
172. Lee D.K., George S.R., Evans J.F., Lynch K.R., O'Dowd B.F. Orphan G protein-coupled receptors in the CNS. Curr. Opin. Pharmacol. 1:2001;31-39.
173. Lee S.P., Xie Z., Varghese G., Nguyen T., O'Dowd B.F., George S.R. Oligomerization of dopamine and serotonin receptors. Neuropsychopharmacology. 23:2000;S32-40.
174. 1 receptor-null mice. J. Clin. Invest. 104:1999;1731-1737.
175. Levac B.A., O'Dowd B.F., George S.R. Opioids: molecular basis of action. Curr. Opin. Endocrinol. Diabetes. 8:2001;166-171.
176. Levac B.A., O'Dowd B.F., George S.R. Oligomerization of opioid receptors: generation of novel signaling units. Curr. Opin. Pharmacol. 2:2002;76-81.
177. Levey A.I. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 93:1996;13541-13546.
178. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 298:2001;1007-1014.
179. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 98:1999;365-376.
180. 2-adrenergic receptor subtypes b and c. Science. 273:1996;803-805.
181. 2c-adrenoceptor homolog. Mol. Pharmacol. 48:1995;48-55.
182. 4) expressed in bone marrow. Mol. Pharmacol. 59:2001;420-426.
183. Liu C., Weaver D.R., Jin X., Shearman L.P., Pieschl R.L., Gribkoff V.K., Reppert S.M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 19:1997;91-102.
184. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J., Liu C.H., Hla T., Spiegel S., Proia R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106:2000;951-961.
185. Loh H.H., Liu H.C., Cavalli A., Yang W., Chen Y.F., Wei L.N. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol. Brain Res. 54:1998;321-326.
186. Low M.J., Otero-Corchon V., Parlow A.F., Ramirez J.L., Kumar U., Patel Y.C., Rubinstein M. Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth. J. Clin. Invest. 107:2001;1571-1580.
187. 1D antagonist GR127935. Mol. Pharmacol. 51:1997;755-763.
188. 4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. USA. 95:1998;9448-9453.
189. 2a-adrenergic receptor subtype. Science. 273:1996;801-803.
190. Malagie I., Trillat A.C., Bourin M., Jacquot C., Hen R., Gardier A.M. 5-HT1B Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex. J. Neurochem. 76:2001;865-871.
191. 2 receptors. Nature. 388:1997;586-589.
192. Malleret G., Hen R., Guillou J.L., Segu L., Buhot M.C. 5-HT1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. J. Neurosci. 19:1999;6157-6168.
193. Mamiya T., Noda Y., Nishi M., Takeshima H., Nabeshima T. Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice. Brain Res. 783:1998;236-240.
194. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., Takeshima H. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature. 394:1998;577-581.
195. Mansikka H., Sheth R.N., DeVries C., Lee H., Winchurch R., Raja S.N. Nerve injury-induced mechanical but not thermal hyperalgesia is attenuated in neurokinin-1 receptor knockout mice. Exp. Neurol. 162:2000;343-349.
196. Mansikka H., Shiotani M., Winchurch R., Raja S.N. Neurokinin-1 receptors are involved in behavioral responses to high-intensity heat stimuli and capsaicin-induced hyperalgesia in mice. Anesthesiology. 90:1999;1643-1649.
197. 5 neuropeptide Y receptor in limbic seizures. Proc. Natl. Acad. Sci. USA. 96:1999;13518-13523.
198. 5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 4:1998;718-721.
199. 1 knockout mice. Eur. J. Neurosci. 12:2000;4038-4046.
200. 1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes. 50:2001;385-391.
201. 1 receptor knockout mice. Eur. J. Pharmacol. 383:1999;R1-2.
202. 3 subtype. Proc. Natl. Acad. Sci. USA. 97:2000;9579-9584.
203. 2 as a mediator of allergic asthma. Science. 287:2000;2013-2017.
204. Matsusaka T., Nishimura H., Utsunomiya H., Kakuchi J., Niimura F., Inagami T., Fogo A., Ichikawa I. Chimeric mice carrying 'regional' targeted deletion of the angiotensin type 1A receptor gene. Evidence against the role for local angiotensin in the in vivo feedback regulation of renin synthesis in juxtaglomerular cells. J. Clin. Invest. 98:1996;1867-1877.
205. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
206. Matthes H.W., Smadja C., Valverde O., Vonesch J.L., Foutz A.S., Boudinot E., Denavit-Saubie M., Severini C., Negri L., Roques B.P., Maldonado R., Kieffer B.L. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J. Neurosci. 18:1998;7285-7295.
207. 1B receptor mutant mice. J. Pharmacol. Exp. Ther. 298:2001;1101-1107.
208. Merali Z., McIntosh J., Anisman H. Role of bombesin-related peptides in the control of food intake. Neuropeptides. 33:1999;376-386.
209. 2 receptor deficient mice. Neuroscience. 79:1997;323-327.
210. 1 receptor deficient mice. Neuroreport. 6:1995;2314-2316.
211. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78:1998;189-225.
212. 1 muscarinic acetylcholine receptor. J. Neurosci. 21:2001;5239-5250.
213. 1A dopamine receptors. Brain Res. 894:2001;167-180.
214. Mizoguchi H., Narita M., Oji D.E., Suganuma C., Nagase H., Sora I., Uhl G.R., Cheng E.Y., Tseng L.F. The mu-opioid receptor gene - dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in mu-opioid receptor knockout mice. Neuroscience. 94:1999;203-207.
215. 1 receptor in pain perception: a study of the receptor gene knockout mice. Eur. J. Pharmacol. 391:2000;81-89.
216. Mogil J.S., Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev. 53:2001;381-415.
217. Montkowski A., Poettig M., Mederer A., Holsboer F. Behavioural performance in three substrains of mouse strain 129. Brain Res. 762:1997;12-18.
218. 1 dopamine receptor. Proc. Natl. Acad. Sci. USA. 93:1996;14928-14933.
219. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., Mahler J.F., Kluckman K.D., Ledford A., Lee C.A., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
220. Morse K.L., Behan J., Laz T.M., West R.E. Jr., Greenfeder S.A., Anthes J.C., Umland S., Wan Y., Hipkin R.W., Gonsiorek W., Shin N., Gustafson E.L., Qiao X., Wang S., Hedrick J.A., Greene J., Bayne M., Monsma F.J. Jr. Cloning and characterization of a novel human histamine receptor. J. Pharmacol. Exp. Ther. 296:2001;1058-1066.
221. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Oh-ishi S., Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 388:1997;678-682.
222. 2 receptor-deficient mice. Neuroscience. 99:2000;643-650.
223. Murtra P., Sheasby A.M., Hunt S.P., De Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature. 405:2000;180-183.
224. Nagata A., Ito M., Iwata N., Kuno J., Takano H., Minowa O., Chihara K., Matsui T., Noda T. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;11825-11830.
225. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis. 26:2000;99-109.
226. 4R. Biochem. Biophys. Res. Commun. 279:2000;615-620.
227. 2 receptors on neuropeptide Y-induced sensitization to sedation. J. Neurochem. 78:2001;1201-1207.
228. Naveilhan P., Canals J.M., Valjakka A., Vartiainen J., Arenas E., Ernfors P. Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. Eur. J. Neurosci. 13:2001;2241-2246.
229. 2 receptor. Nat. Med. 5:1999;1188-1193.
230. Naveilhan P., Hassani H., Lucas G., Blakeman K.H., Hao J.X., Xu X.J., Wiesenfeld-Hallin Z., Thoren P., Ernfors P. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature. 409:2001;513-517.
231. Nebigil C.G., Choi D.S., Dierich A., Hickel P., Le Meur M., Messaddeq N., Launay J.M., Maroteaux L. Serotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. USA. 97:2000;9508-9513.
232. Nelson R.J. The use of genetic 'knockout' mice in behavioral endocrinology research. Horm. Behav. 31:1997;188-196.
233. Nelson R.J., Young K.A. Behavior in mice with targeted disruption of single genes. Neurosci. Biobehav. Rev. 22:1998;453-462.
234. Nguyen T., Shapiro D.A., George S.R., Setola V., Lee D.K., Cheng R., Rauser L., Lee S.P., Lynch K.R., Roth B.L., O'Dowd B.F. Discovery of a novel member of the histamine receptor family. Mol. Pharmacol. 59:2001;427-433.
235. Nicholas A.P., Hokfelt T., Pieribone V.A. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol. Sci. 17:1996;245-255.
236. Niimura F., Labosky P.A., Kakuchi J., Okubo S., Yoshida H., Oikawa T., Ichiki T., Naftilan A.J., Fogo A., Inagami T., et al. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J. Clin. Invest. 96:1995;2947-2954.
237. Nishi M., Houtani T., Noda Y., Mamiya T., Sato K., Doi T., Kuno J., Takeshima H., Nukada T., Nabeshima T., Yamashita T., Noda T., Sugimoto T. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J. 16:1997;1858-1864.
238. Nishimori K., Young L.J., Guo Q., Wang Z., Insel T.R., Matzuk M.M. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc. Natl. Acad. Sci. USA. 93:1996;11699-11704.
239. Oda T., Morikawa N., Saito Y., Masuho Y., Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 275:2000;36781-36786.
240. Ohki-Hamazaki H. Neuromedin B. Prog. Neurobiol. 62:2000;297-312.
241. Ohki-Hamazaki H., Sakai Y., Kamata K., Ogura H., Okuyama S., Watase K., Yamada K., Wada K. Functional properties of two bombesin-like peptide receptors revealed by the analysis of mice lacking neuromedin B receptor. J. Neurosci. 19:1999;948-954.
242. Ohki-Hamazaki H., Wada E., Matsui K., Wada K. Cloning and expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse. Brain Res. 762:1997;165-172.
243. Ohki-Hamazaki H., Watase K., Yamamoto K., Ogura H., Yamano M., Yamada K., Maeno H., Imaki J., Kikuyama S., Wada E., Wada K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature. 390:1997;165-169.
244. Ohtsu H., Tanaka S., Terui T., Hori Y., Makabe-Kobayashi Y., Pejler G., Tchougounova E., Hellman L., Gertsenstein M., Hirasawa N., Sakurai E., Buzas E., Kovacs P., Csaba G., Kittel A., Okada M., Hara M., Mar L., Numayama-Tsuruta K., Ishigaki-Suzuki S., Ohuchi K., Ichikawa A., Falus A., Watanabe T., Nagy A. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 502:2001;53-56.
245. 1B receptors for angiotensin II. Proc. Natl. Acad. Sci. USA. 95:1998;15496-15501.
246. Parish C.L., Finkelstein D.I., Drago J., Borrelli E., Horne M.K. The role of dopamine receptors in regulating the size of axonal arbors. J. Neurosci. 21:2001;5147-5157.
247. 2 mRNA expression in the brain of mu-opioid receptor knockout mice. Brain Res. 894:2001;311-315.
248. Park Y., Ho I.K., Jang C.G., Tanaka S., Ma T., Loh H.H., Ko K.H. Effects of morphine on pentobarbital-induced responses in mu-opioid receptor knockout mice. Brain Res. Bull. 54:2001;527-531.
249. 1A receptor. Proc. Natl. Acad. Sci. USA. 95:1998;10734-10739.
250. 1A receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission. J. Neurochem. 77:2001;607-617.
251. 1 receptor. Nat. Med. 4:1998;722-726.
252. 1 receptors. Proc. Natl. Acad. Sci. USA. 97:2000;8140-8145.
253. 2 receptors. Nat. Neurosci. 1:1998;610-615.
254. Phillips T.J., Hen R., Crabbe J.C. Complications associated with genetic background effects in research using knockout mice. Psychopharmacol. (Berl.). 147:1999;5-7.
255. Picciotto M.R. Knock-out mouse models used to study neurobiological systems. Crit. Rev. Neurobiol. 13:1999;103-149.
256. 1B knock-out mice. Neuroreport. 7:1995;353-359.
257. Poulsen S.A., Quinn R.J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 6:1998;619-641.
258. Qiu C., Sora I., Ren K., Uhl G., Dubner R. Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. Eur. J. Pharmacol. 387:2000;163-169.
259. 4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci. 19:1999;4627-4633.
260. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., Mann J.J., Brunner D., Hen R. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. USA. 95:1998;14476-14481.
261. 1B receptor knock out - behavioral consequences. Behav. Brain Res. 73:1996;305-312.
262. 1 receptor knock-out mice. Eur. J. Pharmacol. 379:1999;R1-2.
263. Reinscheid R.K., Nothacker H., Civelli O. The orphanin FQ/nociceptin gene: structure, tissue distribution of expression and functional implications obtained from knockout mice. Peptides. 21:2000;901-906.
264. Ribeiro J.A. Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Eur. J. Pharmacol. 375:1999;101-113.
265. 1B receptors. Alcohol Clin. Exp. Res. 20:1996;1401-1405.
266. 2 receptor knockout mice. Psychopharmacol. (Berl.). 152:2000;343-350.
267. Roberts A.J., Gold L.H., Polis I., McDonald J.S., Filliol D., Kieffer B.L., Koob G.F. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin. Exp. Res. 25:2001;1249-1256.
268. 1B receptors. Pharmacol. Biochem. Behav. 57:1997;407-412.
269. Rocha B.A., Scearce-Levie K., Lucas J.J., Hiroi N., Castanon N., Crabbe J.C., Nestler E.J., Hen R. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature. 393:1998;175-178.
270. 2-adrenergic receptors. J. Biol. Chem. 274:1999;16701-16708.
271. 1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl. Acad. Sci. USA. 93:1996;7375-7380.
272. Rohrer D.K., Kobilka B.K. G protein-coupled receptors: functional and mechanistic insights through altered gene expression. Physiol. Rev. 78:1998;35-52.
273. 4 receptor-deficient mice display cortical hyperexcitability. J. Neurosci. 21:2001;3756-3763.
274. Rubinstein M., Mogil J.S., Japon M., Chan E.C., Allen R.G., Low M.J. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA. 93:1996;3995-4000.
275. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 90:1997;991-1001.
276. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. 39:2000;1413-1421.
277. Sadee W., Hoeg E., Lucas J., Wang D. Genetic variations in human G protein-coupled receptors: implications for drug therapy. AAPS PharmSci. 3:2001;E22.
278. 2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. USA. 99:2002;8938-8943.
279. 2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry. 4:1999;443-452.
280. 2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J. Neurosci. 18:1998;3035-3042.
281. 2C-adrenergic receptor subtype. Neuroscience. 86:1998;959-965.
282. Sallinen J., Link R.E., Haapalinna A., Viitamaa T., Kulatunga M., Sjoholm B., Macdonald E., Pelto-Huikko M., Leino T., Barsh G.S., Kobilka B.K., Scheinin M. Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol. Pharmacol. 51:1997;36-46.
283. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:2000;4429-4434.
284. Santarelli L., Gobbi G., Debs P.C., Sibille E.T., Blier P., Hen R., Heath M.J. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. USA. 98:2001;1912-1917.
285. 1A receptors. Proc. Natl. Acad. Sci. USA. 97:2000;14731-14736.
286. 1B receptor. Science. 265:1994;1875-1878.
287. Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods. 14:1998;381-392.
288. 1B receptor. Psychopharmacol. (Berl.). 141:1999;154-161.
289. 2-adrenoceptor subtype-deficient mice. Br. J. Pharmacol. 132:2001;925-933.
290. Schlussman S.D., Ho A., Zhou Y., Curtis A.E., Kreek M.J. Effects of 'binge' pattern cocaine on stereotypy and locomotor activity in C57BL/6J and 129/J mice. Pharmacol. Biochem. Behav. 60:1998;593-599.
291. 3 receptors. J. Biol. Chem. 275:2000;38944-38948.
292. 2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21:2001;5916-5924.
293. 2a-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21:2001;4875-4882.
294. Schuller A.G., King M.A., Zhang J., Bolan E., Pan Y.X., Morgan D.J., Chang A., Czick M.E., Unterwald E.M., Pasternak G.W., Pintar J.E. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. 2:1999;151-156.
295. 4-deficient mice. Biochem. Biophys. Res. Commun. 246:1998;7-12.
296. Shapiro M.S., Loose M.D., Hamilton S.E., Nathanson N.M., Gomeza J., Wess J., Hille B. Assignment of muscarinic receptor subtypes mediating G-protein modulation of Ca(2+) channels by using knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;10899-10904.
297. Sharifi N., Diehl N., Yaswen L., Brennan M.B., Hochgeschwender U. Generation of dynorphin knockout mice. Mol. Brain Res. 86:2001;70-75.
298. 1A receptors in mood disorders: a combined genetic and genomic approach. Behav. Pharmacol. 12:2001;429-438.
299. A receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20:2000;2758-2765.
300. 3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur. J. Pharmacol. 414:2001;189-195.
301. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., Le Meur M., Roques B.P., Maldonado R., Kieffer B.L. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17:1998;886-897.
302. Slowe S.J., Simonin F., Kieffer B., Kitchen I. Quantitative autoradiography of mu-, delta- and kappa1 opioid receptors in kappa-opioid receptor knockout mice. Brain Res. 818:1999;335-345.
303. 1A dopamine receptors. Neuroscience. 86:1998;135-146.
304. 2A receptor. Brain Res. 877:2000;160-169.
305. 2A receptor. Neurosci. Lett. 291:2000;97-100.
306. Sora I., Elmer G., Funada M., Pieper J., Li X.F., Hall F.S., Uhl G.R. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology. 25:2001;41-54.
307. Sora I., Funada M., Uhl G.R. The mu-opioid receptor is necessary for[D-Pen2,D-Pen5]enkephalin-induced analgesia. Eur. J. Pharmacol. 324:1997;R1-2.
308. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA. 94:1997;1544-1549.
309. Spreng M., Cotecchia S., Schenk F. A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities. Neurobiol. Learn. Mem. 75:2001;214-229.
310. 1 cannabinoid receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5786-5790.
311. 3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol. Behav. 63:1997;137-141.
312. Stout S.C., Owens M.J., Nemeroff C.B. Neurokinin 1 receptor antagonists as potential antidepressants. Annu. Rev. Pharmacol. Toxicol. 41:2001;877-906.
313. Sugimoto Y., Yamasaki A., Segi E., Tsuboi K., Aze Y., Nishimura T., Oida H., Yoshida N., Tanaka T., Katsuyama M., Hasumoto K., Murata T., Hirata M., Ushikubi F., Negishi M., Ichikawa A., Narumiya S. Failure of parturition in mice lacking the prostaglandin F receptor. Science. 277:1997;681-683.
314. Sun D., Samuelson L.C., Yang T., Huang Y., Paliege A., Saunders T., Briggs J., Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc. Natl. Acad. Sci. USA. 98:2001;9983-9988.
315. Sun W.Y., Witte D.P., Degen J.L., Colbert M.C., Burkart M.C., Holmback K., Xiao Q., Bugge T.H., Degen S.J. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc. Natl. Acad. Sci. USA. 95:1998;7597-7602.
316. Susulic V.S., Frederich R.C., Lawitts J., Tozzo E., Kahn B.B., Harper M.E., Himms-Hagen J., Flier J.S., Lowell B.B. Targeted disruption of the beta 3-adrenergic receptor gene. J. Biol. Chem. 270:1995;29483-29492.
317. 2C-adrenoceptor gene. Eur. J. Neurosci. 11:1999;599-603.
318. Tanimoto K., Sugiyama F., Goto Y., Ishida J., Takimoto E., Yagami K., Fukamizu A., Murakami K. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 269:1994;31334-31337.
319. 2C serotonin receptors. Nature. 374:1995;542-546.
320. 5 receptor. Pharmacol. Biochem. Behav. 67:2000;683-691.
321. 2. J. Clin. Invest. 102:1998;1994-2001.
322. Thomas S.A., Matsumoto A.M., Palmiter R.D. Noradrenaline is essential for mouse fetal development. Nature. 374:1995;643-646.
323. Tian M., Broxmeyer H.E., Fan Y., Lai Z., Zhang S., Aronica S., Cooper S., Bigsby R.M., Steinmetz R., Engle S.J., Mestek A., Pollock J.D., Lehman M.N., Jansen H.T., Ying M., Stambrook P.J., Tischfield J.A., Yu L. Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J. Exp. Med. 185:1997;1517-1522.
324. 1B receptors: in vivo microdialysis studies. J. Neurochem. 69:1997;2019-2025.
325. Ueda H., Yamaguchi T., Tokuyama S., Inoue M., Nishi M., Takeshima H. Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene. Neurosci. Lett. 237:1997;136-138.
326. 3. Nature. 395:1998;281-284.
327. 2 receptors. Nature. 408:2000;199-203.
328. 1 receptors. Eur. J. Neurosci. 12:2000;533-539.
329. 6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. Clin. Invest. 107:2001;R37-45.
330. Wada E., Watase K., Yamada K., Ogura H., Yamano M., Inomata Y., Eguchi J., Yamamoto K., Sunday M.E., Maeno H., Mikoshiba K., Ohki-Hamazaki H., Wada K. Generation and characterization of mice lacking gastrin-releasing peptide receptor. Biochem. Biophys. Res. Commun. 239:1997;28-33.
331. Waddington J.L., Clifford J.J., McNamara F.N., Tomiyama K., Koshikawa N., Croke D.T. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;925-964.
332. 2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 20:2000;8305-8314.
333. 1b receptor is not necessary for reproductive and circadian responses to melatonin in Siberian hamsters. Mol. Endocrinol. 10:1996;1478-1487.
334. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 31:2001;453-462.
335. Wynick D., Small C.J., Bacon A., Holmes F.E., Norman M., Ormandy C.J., Kilic E., Kerr N.C., Ghatei M., Talamantes F., Bloom S.R., Pachnis V. Galanin regulates prolactin release and lactotroph proliferation. Proc. Natl. Acad. Sci. USA. 95:1998;12671-12676.
336. 1 receptor. Brain. 852:2000;198-207.
337. 1 receptor mutant mice. Cell. 79:1994;945-955.
338. 3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 19:1997;837-848.
339. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 79:1994;729-742.
340. Yamada K., Ohki-Hamazaki H., Wada K. Differential effects of social isolation upon body weight, food consumption, and responsiveness to novel and social environment in bombesin receptor subtype-3 (BRS-3) deficient mice. Physiol. Behav. 68:2000;555-561.
341. Yamada K., Wada E., Imaki J., Ohki-Hamazaki H., Wada K. Hyperresponsiveness to palatable and aversive taste stimuli in genetically obese (bombesin receptor subtype-3-deficient) mice. Physiol. Behav. 66:1999;863-867.
342. Yamada K., Wada E., Wada K. Female gastrin-releasing peptide receptor (GRP-R)-deficient mice exhibit altered social preference for male conspecifics: implications for GRP/GRP-R modulation of GABAergic function. Brain Res. 894:2001;281-287.
343. Yamada K., Wada E., Wada K. Male mice lacking the gastrin-releasing peptide receptor (GRP-R) display elevated preference for conspecific odors and increased social investigatory behaviors. Brain Res. 870:2000;20-26.
344. 5 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA. 98:2001;14096-14101.
345. 3 muscarinic acetylcholine receptor are hypophagic and lean. Nature. 410:2001;207-212.
346. 2 receptor plays a critical role in cell proliferation and proopiomelanocortin expression in the pituitary. Genes Cells. 1:1996;253-268.
347. 1 receptors. Neuroscience. 87:1998;479-487.
348. Yaswen L., Diehl N., Brennan M.B., Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med. 5:1999;1066-1070.
349. 5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci. 68:2001;2449-2456.
350. 2 vasopressin receptor gene. J. Clin. Invest. 106:2000;1361-1371.
351. 2 receptors. J. Neurosci. 20:2000;5949-5957.
352. Zheng H., Bailey A., Jiang M.H., Honda K., Chen H.Y., Trumbauer M.E., Van der Ploeg L.H., Schaeffer J.M., Leng G., Smith R.G. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol. Endocrinol. 11:1997;1709-1717.
353. Zhou Q.Y., Quaife C.J., Palmiter R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature. 374:1995;640-643.
354. 5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:1998;4018-4025.
355. Zhu Y., King M.A., Schuller A.G., Nitsche J.F., Reidl M., Elde R.P., Unterwald E., Pasternak G.W., Pintar J.E. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 24:1999;243-252.
356. Zhu Y., Michalovich D., Wu H., Tan K.B., Dytko G.M., Mannan I.J., Boyce R., Alston J., Tierney L.A., Li X., Herrity N.C., Vawter L., Sarau H.M., Ames R.S., Davenport C.M., Hieble J.P., Wilson S., Bergsma D.J., Fitzgerald L.R. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 59:2001;434-441.
357. Zimmer A., Valjent E., Konig M., Zimmer A.M., Robledo P., Hahn H., Valverde O., Maldonado R. Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J. Neurosci. 21:2001;9499-9505.
358. Zimmer A., Zimmer A.M., Baffi J., Usdin T., Reynolds K., Konig M., Palkovits M., Mezey E. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc. Natl. Acad. Sci. USA. 95:1998;2630-2635.
359. 1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780-5785.